Curated News
By: NewsRamp Editorial Staff
January 28, 2025
Aclarion, Inc. Announces Reverse Stock Split Timing and Ratio
TLDR
- Aclarion, Inc. announces a revised 1-for-335 reverse stock split, aiming to meet Nasdaq listing standards and boost stock price.
- Aclarion leverages MRS, signal processing techniques, and biomarkers to optimize clinical treatments, starting with Nociscan for chronic low back pain.
- Aclarion's innovative technology helps physicians locate chronic low back pain non-invasively, providing clarity for treatment optimization and patient relief.
- Aclarion's Nociscan platform uses cutting-edge MRI data analysis and augmented intelligence algorithms to improve diagnosis and treatment of chronic low back pain.
Impact - Why it Matters
This news matters as it demonstrates Aclarion, Inc.'s strategic move to enhance its stock value and meet Nasdaq listing standards. The reverse stock split reflects the company's commitment to optimizing its financial position and providing more clarity for investors.
Summary
Aclarion, Inc. announces revised timing and split ratio for a pending reverse stock split of its common stock. The reverse stock split is set at 1-for-335 and will be effective before market open on January 30, 2025. The Company expects this action to help meet Nasdaq listing standards.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Aclarion, Inc. Announces Reverse Stock Split Timing and Ratio
